SEATTLE, Wa., January 6, 2017 - Adaptive Biotechnologies, the leader in combining next-generation sequencing (NGS) and expert bioinformatics to profile T- and B-cell receptors of the adaptive immune system, announces it has entered into an agreement with Amgen to further develop and commercialize Adaptive’s NGS-based clonoSEQ Assay to assess minimal residual disease (MRD) in patients with Acute Lymphoblastic Leukemia (ALL).
BREAKING NEWS FROM ADAPTIVE
Adaptive Biotechnologies, a leader and pioneer in next generation sequencing (NGS) of T-cell and B-cell receptors in the immune system, announced today the completion of Adaptive’s Series F financing round with a $195 million investment to support several strategic growth initiatives. This round was led by Matrix Capital Management and included other new investors Senator Investment Group, Tiger Management, Rock Springs Capital and an additional large healthcare investor, alongside participation from existing investors Viking Global, Casdin Capital and Alexandria Real Estate Equities. Adaptive is also backed by industry-leading strategic investors Illumina, Celgene, BD Biosciences and LabCorp.
SEATTLE, WA - Adaptive Biotechnologies today announced the recent publication of a study conducted with researchers at The University of Texas MD Anderson Cancer Center showing that the company’s next-generation sequencing-based approach to identification and quantification of populations of B cells can detect tumor-specific DNA sequences in the blood of people with classical Hodgkin’s lymphoma (CHL).
SEATTLE, WA – Adaptive Biotechnologies today announced the recent publication of a study demonstrating that analysis of circulating tumor DNA (ctDNA) using the company’s next-generation sequencing-based minimal residual disease detection and quantification method (clinically-available as the clonoSEQ™ MRD test) can detect relapse in diffuse large B-cell lymphoma (DLBCL) patients with significantly higher specificity than positron emission tomography combined with CT (PET/CT).
Seattle, WA – Adaptive Biotechnologies, the company pioneering Next Generation Sequencing (NGS) applications for cancer immunology, and its collaborators will present data demonstrating how profiling a patient’s T-cell repertoire may inform clinical care in patients with melanoma and other solid tumors at the American Association for Cancer Research® (AACR) meeting in Philadelphia from April 18-22, 2015.
NORWALK, Conn. & SEATTLE – April 14, 2015 – The Multiple Myeloma Research Foundation (MMRF), in collaboration with the University of Torino (UofT) and Adaptive Biotechnologies, today announced a collaboration to perform sequencing-based assessment of minimal residual disease (MRD) on hundreds of multiple myeloma (MM) patients over a five year period. The purpose of this initiative is to investigate a new approach to monitoring MRD.
SEATTLE, April 1, 2015 -- Adaptive Biotechnologies today announced publication of a study in The Lancet Oncology showing that analysis of circulating tumor DNA (ctDNA) using the company’s next-generation sequencing-based minimal residual disease (MRD) detection and quantification technology (available clinically as the clonoSEQ™ MRD test) accurately identifies patients with diffuse large B-cell lymphoma (DLBCL) who are at risk of relapse after initial treatment, usually several months before disease can be detected via computed tomography (CT). The study, conducted with co
Seattle, WA - Adaptive Biotechnologies announced today that members of the company's management team will present at upcoming 2015 conferences.
Chad Robins, Chief Executive Officer and President, will present at the Goldman Sachs Investor Conference on March 17th in New York, NY. Alongside Dr. Michael Pellini of Foundation Medicine and Eric Schadt of the Icahn Institute for Genomics, the panel will discuss how innovation can be disruptive across key sectors of the healthcare industry.
Seattle, WA - Adaptive Biotechnologies announced today that Chad Cohen, Zillow Group CFO, is joining its Board of Director as Chair of the Audit Committee.
SEATTLE - Adaptive Biotechnologies Corporation, a pioneer in leveraging next generation sequencing to profile T-cell and B-cell receptors, today announced the acquisition of Sequenta, Inc. which is expected to expedite and expand the use of novel immunosequencing products for researchers and clinicians to diagnose, treat, and monitor patients with cancer, autoimmune disorders, and infectious diseases.
Seattle, WA - Adaptive Biotechnologies, the pioneer of Next Generation Sequencing (NGS) of the adaptive immune system, and its collaborators will present data demonstrating how immunosequencing can inform clinical care in patients with blood cancers at the American Society of Hematology (ASH) meeting from December 6-9, 2014.